EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
|
|
- Frederica McCoy
- 5 years ago
- Views:
Transcription
1 EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy
2 The EGFR/HER Family Ligand binding domain Transmembrane erb-b1 EGFR HER1 neu Erb-b2 HER2 Erb-b3 HER3 Erb-b4 HER4 = Tyrosine Kinase Domain
3 EGFR Tyrosine Kinase Inhibitors Reversible Irreversible Gefitinib EKB-586 Erlotinib CI 1033 Lapatinib HKI-272 PF BIBW 2992 CL
4 EGFR-TKIs efficacy in unselected NSCLC Reference # Line Drug RR (%) PFS (months) OS (months) Akerley 40 I Erlotinib Hesketh 81 I Erlotinib Jackman 80 I Erlotinib Giaccone 53 I Erlotinib Govindan 198 I Gefitinib 6.3 NR 6 Niho 42 I Gefitinib 30 NR 13.9 West 136 I/II Gefitinib 17 NR 13 Janne 200 I/II+ Gefitinib 4.1 NR 4.5 Kubota 62 II/III Erlotinib Perng 299 II/III Erlotinib NR Perez-Soler 57 II/III Erlotinib Fukuoka 210 II/III Gefitinib Cappuzzo 106 II/III Gefitinib Kris 216 III Gefitinib 12 NR 7 Simon 183 I/II/III+ Gefitinib Chen 36 II/III/IV Gefitinib Felip 83 II/III/IV Erlotinib
5 EGFR-TKI single agent versus CT or placebo in first-line unselected NSCLC: phase II randomized studies PS 2: Lilenbaum UNFIT FOR CHEMO: INSTEP Stratified by: Center Age (< 70 vs > 70) Extent of Disease (Stage IIIB vs IV) R A N D O M I Z E Erlotinib 150 mg daily Carboplatin AUC 6 + Paclitaxel 200 mg/m 2 Randomize d Phase II study NSCLC wet IIIB/IV PS 2-3 unfit for CT Gefitinib 250 mg/day + BSC BSC 1: 1 Day 1 q 21 days x 4 cycles ELDERLY: INVITE Phase II (open-label) Stage IIIB/IV NSCLC Chemonaïve >70 years WHO PS 0-2 1:1 randomization Gefitinib 250 mg/day (n=97) Vinorelbine 30 mg/m 2 on Days 1 & 8 of 21-day cycle (n=99) Primary endpoint: Progression-free survival (PFS) Secondary endpoints: Overall survival Response rate Quality of life Pulmonary symptom improvement Tolerability Exploratory endpoints: EGFR biomarkers
6 EGFR-TKIs in unselected NSCLC: better than nothing but worse than chemotherapy Study N Drug RR (%) PFS (months) HR OS (months) HR INVITE Gefitinib Vinorelbine INSTEP Gefitinib Placebo Lilenbaum Erlotinib Carbo/taxol
7 Predictive Factors for EGFR-TKI Sensitivity Clinical Biological Predictive for Response Gender Histology Smoking history Ethnicity EGFR Gene mutation EGFR high copy number HER2 high copy number Akt activation Predictive for Survival Smoking history Response to prior therapy PS Histology Previous Platinum Skin rash Ethnicity EGFR gene mutation EGFR high copy number Primary Resistance Predictive for Resistance K-Ras Mutation EGFR exon 20 insertion HER2 exon 20 mutation Acquired Resistance EGFR T790M-D761Y MET Amplification
8 Response to TKIs According to EGFR Status in Retrospective and Prospective Studies Reference # Method Study RR (%) p value EGFR+ EGFR- Cappuzzo 102 FISH Retrosp <0.001 Cappuzzo 36 FISH Prospec <0.001 FISH: Response rate up to 68% Hirsch 81 FISH Retrosp Hirsch 370 FISH Retrosp <0.001 Tsao 221 FISH Retrosp Mitsudomi 59 MUT Retrosp < Takano 66 MUT Retrosp < Mutation: Response rate up to 82% Cappuzzo 37 MUT Prospec Paz-Ares 127 MUT Prospec Sequist 31 MUT Prospec
9 Prospective studies of EGFR-TKI in EGFR Mutated NSCLC Reference # Selection criterion Line Drug RR (%) PFS (months) OS (months) Asahina 16 EGFR mutation I Gefitinib Not reached Inoue 30 EGFR mutation I Gefitinib Inoue 16 EGFR mutation I Gefitinib Not reported Kimura 13 EGFR mutation I Gefitinib Rosell 217 EGFR mutation I/II Erlotinib Rosell 12 EGFR mutation I Erlotinib >28.0 Sequist 34 EGFR mutation I Gefitinib Yang 55 EGFR mutation I Gefitinib Sugio 20 EGFR mutation I/II Gefitinib Sunaga 21 EGFR mutation I/II Gefitinib Not reached Sutani 38 EGFR mutation I/II Gefitinib Yoshida 27 EGFR mutation I/II Gefitinib Not reached Han 17 EGFR mutation I/II+ Gefitinib Tamura 28 EGFR mutation I/II/III Gefitinib Not reached
10 EGFR-TKIs versus chemotherapy in firstline: Phase III trials in clinically selected patients IPASS Chemonaive Age> 18 Adenocarcinoma Never/light smokers ECOG PS:0-2 Stage IIIB-IV 1 R 1 Gefitinib (250 mg / day) Carboplatin (AUC 5 or 6) / paclitaxel (200 mg / m 2 ) 3 weekly # FIRST SIGNAL Primary end-point: PFS Chemonaive Age years Adenocarcinoma Never smokers ECOG PS:0-2 Stage IIIB-IV 1 R Gefitinib (250 mg / day) 1 Gemcitabine 1250 mg/mq 1,8 Cisplatin 80 mg/mq 1 Q 21 days, up to 9 cycles
11 IPASS:PFS in ITT population Probability of PFS 0.8 N Events Gefitinib (74.4%) Carboplatin / paclitaxel (81.7%) HR (95% CI) = (0.651, 0.845) p< Median PFS (months) 4 months progression-free 6 months progression-free 12 months progression-free % 48% 25% % 48% 7% 12 months progression-free 25% 7% Gefitinib demonstrated superiority relative to carboplatin / paclitaxel in terms of PFS At risk : Gefitinib Carboplatin / paclitaxel Months Primary Cox analysis with covariates HR <1 implies a lower risk of progression on gefitinib
12 IPASS: Overall Survival in ITT Population Probability of survival N Events Gefitinib Carboplatin / paclitaxel (36.6%) (37.3%) HR (95% CI) = 0.91 (0.76, 1.10) Median OS (months) 6 month OS 12 month OS % 68% % 64% Months At risk : 24 Gefitinib Carboplatin / paclitaxel Cox analysis with covariates HR <1 implies a lower risk of death on gefitinib OS, overall survival
13 Progression-free Survival in EGFR Mutation Positive and Negative Patients: Two Important Findings EGFR mutation positive 1. Maintenance effect 2. EGFR mutant Gefitinib more (n=132) sensitive Carboplatin / paclitaxel (n=129) to chemotherapy Probability of progressio on-free survival At risk : Gefitinib C / P HR (95% CI) = 0.48 (0.36, 0.64) p< No. events gefitinib, 97 (73.5%) No. events C / P, 111 (86.0%) Months Probability of progressio on-free survival EGFR mutation negative We need biological selection Treatment by subgroup interaction test, p< ITT population Cox analysis with covariates Gefitinib (n=91) Carboplatin / paclitaxel (n=85) HR (95% CI) = 2.85 (2.05, 3.98) p< No. events gefitinib, 88 (96.7%) No. events C / P, 70 (82.4%) Months
14 IPASS: overlap of biomarkers High EGFRgene-copy number N= EGFR expression positive N= Positive for all 3 biomarkers N=132 EGFR mutation positive N= N=329 with known biomarker status for all 3 biomarkers Negative for all 3 biomarkers N=31
15 Progression-free survival in high and low EGFR-gene-copy number patients High EGFR-gene-copy number Low EGFR-gene-copy number Probability of pro ogression-free survival At risk : Gefitinib C/P Gefitinib (n=124) Carboplatin/paclitaxel (n=125) HR (95% CI) = 0.66 (0.50, 0.88) p= No. events gefitinib, 98 (79.0%) No. events C/P, 104 (83.2%) Months Probability of pro ogression-free survival Gefitinib (n=81) Carboplatin/paclitaxel (n=76) HR (95% CI) = 1.24 (0.87, 1.76) p= No. events gefitinib, 69 (85.2%) No. events C/P, 68 (89.5%) Treatment by EGFR-gene-copy number interaction test, p= Cox analysis with covariates; HR <1 implies a lower risk of progression on gefitinib; ITT population Months
16
17
18 EGFR-TKIs versus chemotherapy in firstline: Phase III trials in biologically selected patients NEJ002 Chemonaive Age years EGFR mutation+ ECOG PS:0-1 Stage IIIB-IV 1 R 1 Gefitinib (250 mg / day) Carboplatin/ paclitaxel q 3 weeks WJTOG3405 Primary end-point: PFS Chemonaive Age >20 years EGFR Mutation+ ECOG PS:0-1 Stage IIIB-IV 1 R Gefitinib (250 mg / day) 1 docetaxel 60 mg/mq Cisplatin 80 mg/mq Q 21 days, up to 6 cycles
19 Gefitinib more effective than chemotherapy in EGFR Mutation+ NSCLC NEJ002: PFS WJTOG HR % CI 0.25, 0.51 p<0.001 Median 10.4 vs 5.5 months Gef CT p HR Gefitinib RR (%) Carb / pac PFS (months) <
20 SATURN study design Chemonaïve advanced NSCLC n=1,949 4 cycles of 1st-line platinumbased doublet* Non-PD n=889 Erlotinib 150mg/day 1:1 PD Mandatory tumor sampling Placebo PD Stratification factors: EGFR IHC (positive vs negative vs indeterminate) Stage (IIIB vs IV) ECOG PS (0 vs 1) CT regimen (cis/gem vs carbo/doc vs others) Smoking history (current vs former vs never) Region Co-primary endpoints: PFS in all patients PFS in patients with EGFR IHC+ tumors Secondary endpoints: OS in all patients and those with EGFR IHC+ tumors, OS and PFS in EGFR IHC tumors; biomarker analyses; safety; time to symptom progression; QoL *Cisplatin/paclitaxel; cisplatin/gemcitabine; cisplatin/docetaxel cisplatin/vinorelbine; carboplatin/gemcitabine; carboplatin/docetaxel carboplatin/paclitaxel
21 PFS*: all patients (ITT) PFS probability 0.8 Erlotinib Placebo PFS at 12 wks (%) PFS at 24 wks (%) HR=0.71 ( ) Log-rank p< Erlotinib (n=437) Placebo (n=447) Time (weeks) *PFS is measured from time of randomization into the maintenance phase; assessments were every 6 weeks
22 Largest PFS benefit with erlotinib in patients with EGFR mutated tumours EGFR mutation+ EGFR wild-type PFS probab bility HR=0.10 ( ) Log-rank p< Erlotinib (n=22) Placebo (n=27) HR=0.78 ( ) Log-rank p= Erlotinib (n=199) Placebo (n=189) Time (weeks) Time (weeks) Interaction p<0.001
23 ATLAS Study Design Chemo-naïve Advanced NSCLC N=1,160 Eligibility Stage III/IV NSCLC 4 cycles of 1st-line chemotherapy* + bevacizumab ECOG performance status 0-1 Stratification factors Gender Smoking history (never vs former/current) ECOG performance status (0 v >1) Chemotherapy regimen Non-PD n=768 (66%) Bevacizumab + Erlotinib to PD 1:1 Bevacizumab + Placebo to PD Primary endpoint Carbo/paclitaxel; cis/vinorelbine; carbo or cis/gemcitabine; carbo or cis/docetaxel. Unblind at PD PFS in all randomized pts Secondary endpoints Overall survival Safety Exploratory endpoints Post progression therapy Biomarker analyses (IHC, FISH, EGFR & K-Ras mutation)
24 ATLAS: Progression-Free Survival (ITT population, investigator assessment) Without Event Proportion Bev + Placebo (n=373) Bev + Erlotinib (n=370) HR=0.722 ( ) Log-rank P= Progression-Free Survival (months) No. of patients at risk: Bev + Placebo Bev + Erlotinib
25 PFS K-M Curves by EGFR Mutation Status EGFR Wild-Type B+E (n=150) B+P (n=145) Censored value EGFR Mutant B+E (n=27) B+P (n=25) Censored value HR = (95% CI: ) Log-rank P= HR = (95% CI: ) Log-rank P=0.0137
26 IS EGFR MUTATION TESTING THE BEST PREDICTOR FOR PATIENT SURVIVAL?
27 EGFR Mutations: A Positive Prognostic Factor? TRIBUTE INTACT 1&2
28 No trial demonstrated survival benefit for EGFR mutated patients treated with TKIs IPASS SATURN Gefitinib (n=132) Carboplatin / paclitaxel (n=129) Probability of overall survival HR (95% CI) = (0.500, 1.202) No. events gefitinib, 38 (28.8%) No. events C / P, 43 (33.3%) HR=0.83 ( ) Log-rank p= Erlotinib Placebo Time (months) First-SIGNAL Time from randomisation (months)
29 BR21: Survival According to Updated EGFR Mutation Status P=0.12 Hazard ratio, 0.55 (95% CI, ) P=0.09 Hazard ratio, 0.74 (95% CI, ) Interaction P value = 0.47 Shepherd et al, ASCO 2007
30 EGFR Gene Copy Number and Survival in the NSCLC Cohort 1,0,9 1,0,9 p=0.4 CUMULAT TIVE SURVIVAL,8,7,6,5,4,3,2,1 EGFR FISH-: (N=215) EGFR FISH+ : Gene Amplification (GA, N=39) EGFR FISH+: High Polysomy (HP, N=122) Median survival: EGFR FISH-:48.3 months EGFR FISH HP:40.7 months EGFR FISH GA: 30.7 months CUMULAT TIVE SURVIVAL,8,7,6,5,4,3,2,1 EGFR FISH-(N=215) Median survival: EGFR FISH-:48.3 months EGFR FISH+: 40.7 months EGFR FISH+ (N=161), , MONTHS MONTHS At risk Negative HP GA At risk FISH FISH Cappuzzo et al. JCO 2009
31 FISH Predicts Benefit of EGFR-TKIs Proportion surviving ISEL FISH + BR21 FISH + Gefitinib Placebo Erlotinib Placebo Proportion surviving Time (months) ISEL FISH - Cox: p=0.07 HR=0.61 (0.36, 4) Gefitinib Placebo Time (months) BR21 FISH - Erlotinib Placebo Log-rank: p=0.008 HR=0.44 (0.23, 0.82) Cox: p=0.42 HR=1.16 (0.81, 1.64) Log-rank: p=0.59 HR=0.85 (0.48, 1.51) Hirsch 2005 Time (months) Time (months) Tsao 2005
32 Different Effect of Cetuximab and Gefitinib in NSCLC Cell-lines with or without EGFR Mutations EGFR WT EGFR MT Mukohara, T. et al. J. Natl. Cancer Inst. 2005
33 EGFR Mutations and Cetuximab Sensitivity in NSCLC: BMS 099 Data
34 Conclusions EGFR-TKIs should be considered in EGFR mut+ patients as first-line therapy Higher RR Longer PFS At least equal surviva Lower toxicity EGFR mutation is not the best predictor for survival EGFR mutation test is not useful for selection of patients candidate for cetuximab therapy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationLung cancer is the leading cause of cancer death both in the. EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer
STATE OF THE ART: CONCISE REVIEW EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer Thomas Fong, MD,* Daniel Morgensztern, MD,* and Ramaswamy Govindan, MD* Tyrosine kinase inhibitors
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationΕλλάδα Ελευθεριάδου Ειδικός Πνευμονολόγος Επιστημονική συνεργάτης της Πνευμονολογικής Κλινικής ΑΠΘ Νοσοκομείου Παπανικολάου και υποψήφια διδάκτορας
Ελλάδα Ελευθεριάδου Ειδικός Πνευμονολόγος Επιστημονική συνεργάτης της Πνευμονολογικής Κλινικής ΑΠΘ Νοσοκομείου Παπανικολάου και υποψήφια διδάκτορας ΑΠΘ Μετεγχειριτική αντιμετώπιση του ΜΜΚΠ Significant
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationEGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationREVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok
Personalized medicine in lung cancer: what we need to know Tony S. K. Mok Abstract Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes
More informationReview on activated protocols in advanced non-small cell lung cancer. Rolf Stahel Zürich, Switzerland
Review on activated protocols in advanced non-small cell lung cancer Rolf Stahel Zürich, Switzerland Lucerne, 19.1.2008 Case report 1 75 y/o man retired, held many jobs from working as driver, attendant
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationCustomising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Eur Respir Rev 2011; 20: 119, 45 52 DOI: 10.1183/09059180.00007310 CopyrightßERS 2011 REVIEW Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives A.C. Vilmar
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationNon-small cell lung cancer (NSCLC) has been the leading
ORIGINAL ARTICLE EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Federico Cappuzzo, MD,* Claudio Ligorio, PhD, Luca Toschi,
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationGenetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Eur Respir J 2011; 37: 183 193 DOI: 10.1183/09031936.00179409 CopyrightßERS 2011 REVIEW Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer J. Cadranel*,
More informationTreatment of PS 2 Patients with Advanced NSCLC:
Treatment of PS 2 Patients with Advanced NSCLC: Current State of the Art Corey J Langer MD, FACP Director, Thoracic Oncology Abramson Cancer Center Professor of Medicine University of Pennsylvania Philadelpia,
More informationIntroduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationKey Words. Epidermal growth factor receptor EGFR Tyrosine kinase inhibitor TKI Erlotinib Non-small cell lung cancer NSCLC Second-line therapy
The Oncologist Lung Cancer Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? THOMAS E. STINCHCOMBE,MARK A. SOCINSKI Multidisciplinary Thoracic Oncology Program, Lineberger
More informationRESEARCH ARTICLE. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
RESEARCH ARTICLE EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer Satoshi Igawa 1 *, Yuichi Sato 2, Mikiko Ishihara 1, Masashi Kasajima
More information